These studies demonstrated the importance of HDAC3 in the modulation of STAT3 signaling in DLBCL cells and provided the rationale for targeting pSTAT3-positive DLBCL tumors with HDAC inhibitors. The gene discussed is STAT3; the disease is diffuse large B-cell lymphoma.